Erratum

Figures & data

Figure 3. Delayed B16 tumor kinetics in animals intratumorally injected with biodegradable particles encapsulating IL-2. A. poly(lactide-co-glycolide) (PLGA) particles surface modified with anti-CD3 and anti-CD28 and encapsulating IL-2 (described previously in [54]). B. Experimental timeline. Mice received injections of 1 × 10⁵ B16-luciferase cells (Caliper Life Sciences, Hopkinton, MA) subcutaneously on day 0, treated with PLGA microparticles on day 10, and were killed when tumors reached 2 cm². C. Day 10 tumors imaged using Xenogen IVIS-200 (Caliper Life Sciences) following injection of d-Luciferin. Bioluminescence from the tumors (flux) expressed as photons/second/cm²/steridian (photons/sec/cm²/ster). ROI: region of interest, quantified using Living Image Software (Xenogen, Alameda, CA) and analyzed using Igor Pro Image Software (Wavemetrics, Portland, OR). D. Day 10 tumors were treated with a single intratumoral injection of 2 mg of 8 ± 2 μm PLGA particles. Tumor areas were calculated by taking the product of the cross perpendicular diameters which were obtained using tumor calipers. Control particles did not display antibodies or release cytokine. n = 3 (*, ‡, § indicate a 2-way ANOVA with p values of < 0.001, < 0.01, < 0.05, respectively). Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).